Circadia Health Commits $3 million in Respiratory Monitors to Global COVID-19 Efforts

Error message

Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

LONDON, April 02, 2020 (GLOBE NEWSWIRE) -- Circadia Health announces $3 million in medical devices and services towards COVID-19 relief efforts across the globe.

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Thursday, April 2, 2020

Information

Tags:

Health care, Medical device, Health system

Geotags:

London, , GB

Organisation:

CIRCADIA HEALTH

Summary

Key Points:

LONDON, April 02, 2020 (GLOBE NEWSWIRE) -- Circadia Health announces $3 million in medical devices and services towards COVID-19 relief efforts across the globe.
Circadia is committing to an immediate delivery of 2,000 devices and is on track to tripling their manufacturing capacity.
The Circadia C100 facilitates inexpensive and medical grade respiratory monitoring while reducing patient and healthcare provider contact and exposure to COVID-19.
Circadia has started deploying its AI-powered C100 with a large hospital in Los Angeles and is in ongoing discussions with global governments and health systems.

LONDON, April 02, 2020 (GLOBE NEWSWIRE) -- Circadia Health announces $3 million in medical devices and services towards COVID-19 relief efforts across the globe. The company has expedited the release of the Contactless Respiratory Monitoring System (C100) to reduce the workload and risk of exposure on frontline health workers in the COVID-19 response. Circadia is committing to an immediate delivery of 2,000 devices and is on track to tripling their manufacturing capacity.

Circadia recognizes the urgent need for remote contactless monitoring of respiratory status at-scale to help: triage patients in-hospital with early detection and mass-monitoring of vulnerable individuals at-home. The Circadia C100 facilitates inexpensive and medical grade respiratory monitoring while reducing patient and healthcare provider contact and exposure to COVID-19. This follows FDA’s latest guidance to expand the availability and capability of non-invasive remote respiratory monitoring devices.

Circadia has started deploying its AI-powered C100 with a large hospital in Los Angeles and is in ongoing discussions with global governments and health systems.

“The demand for ventilators must be supplemented with the demand for remote monitoring of patients for early detection of respiratory distress. Circadia’s C100 uses AI-powered algorithms and alerts to identify potential worsening of lung function. We have now received exemption from the Malaysian government to ramp up production and are in communication with FDA for expedited review,” says Fares Siddiqui, Chief Executive Officer of Circadia Health.

“Managing and monitoring the influx of patients is overwhelming our global medical systems. Circadia’s proven remote respiratory monitoring of those potentially affected can help prioritize the clinical team’s resources. The need for hands-on review is minimized, with alerts of changes in respiration available if needed. The patients’ progress over time is summarized,” says Chief Medical Advisor, Professor Adrian Williams formerly at Harvard Medical School, UCLA, and former Director of the Lane Fox Respiratory Unit at Guys’ and St Thomas’ Hospital.

About Circadia Health

Circadia (https://circadia.health), HQ in London is a medical technology company enabling early detection of respiratory complications, the third leading cause of death, to save patient lives. Founded in 2016 by Imperial College London alumni Fares Siddiqui and Michal Maslik, Circadia employs engineers, scientists, and physicians to fuse hardware, software, and AI.

Kelsey McGrath, Public Relations
[email protected] | +1 (724) 264-8632

Arnaud Doko, Partnerships
[email protected] | +44 (0) 7426 867 304